& quot ; 1 .
& quot ;
& quot ; Abseamed can be use to reduce exposure to allogeneic blood transfusion in adult non-iron deficient patient prior to major elective orthopaedic surgery , have a high perceive risk for transfusion complication .
& quot ;
& quot ; the target haemoglobin concentration in two study be & gt ; 13 g / dl ; in the remain three study it be 12 - 14 g / dl .
& quot ;
& quot ; Abseamed should be administer intravenously in order to increase haemoglobin to not greater than 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; outer CARTON AND BOTTLE label
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ;
& quot ; 11 .
& quot ;
& quot ; in clinical trial aripiprazole have not be show to induce clinically relevant weight gain ( see section 5.1 ) .
& quot ;
& quot ; the expiry date refers to the last day of that month .
& quot ;
& quot ; other potent inhibitor of CYP3A4 , such a itraconazole and HIV protease inhibitor , may be expect to have similar effect and similar dose reduction should therefore be apply .
& quot ;
& quot ; increase the infusion time from 5 to 15 minute cause a 30 % decrease in zoledronic acid concentration at the end of the infusion , but have no effect on the area under the plasma concentration versus time curve .
& quot ;
& quot ; Smoking status : accord to the metabolic pathway of ABILIFY no dosage adjustment be require for smoker ( see section 4.5 ) .
& quot ;
& quot ; particular attention should be pay to sudden stab migraine- like headache a a possible warning signal .
& quot ;
& quot ; however , a with other antipsychotic , patient should be caution about operate hazardous machine , include motor vehicle , until they be reasonably certain that aripiprazole do not affect them adversely .
& quot ;
& quot ; patient who develop pure red Cell Aplasia ( PRCA ) follow treatment with any erythropoietin should not receive Abseamed or any other erythropoietin ( see section 4.4 - pure red Cell Aplasia ) .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; transferrin saturation be below 20 % .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; 5 .
& quot ;
& quot ; Overdose of epoetin alfa may produce effect that be extension of the pharmacological effect of the hormone .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; these study have show an consistent unexplained statistically significant excess mortality in patient who have anaemia associate with various common cancer who receive recombinant human erythropoietin compare to control .
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; the injection be give in the thigh or the anterior abdominal wall .
& quot ;
& quot ; in intravenous reproductive toxicity study , no new safety concern be observe at maternal exposure up to 15 ( rat ) and 29 ( rabbit ) time human exposure at 30 mg .
& quot ;
& quot ; Hyperglycaemia and Diabetes Mellitus : hyperglycaemia , in some case extreme and associate with ketoacidosis or hyperosmolar coma or death , have be report in patient treat with atypical antipsychotic agent , include ABILIFY .
& quot ;
& quot ; follow any confirm or suspect overdose with aripiprazole , close medical supervision and monitoring should continue until the patient recovers .
& quot ;
& quot ; in the long term 26-week maintenance phase of a placebo-controlled trial , the incidence of EPS be 18.2 % for aripiprazole-treated patient and 15.7 % for placebo-treated patient .
& quot ;
& quot ; 4.4 Special warning and precaution for use
& quot ;
& quot ; there be an increased risk for thromboembolic event in patient with cancer treat with recombinant human erythropoietin and a negative impact on overall survival can not be exclude .
& quot ;
& quot ; it be not know whether aripiprazole be excrete in human milk .
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate .
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; in CYP2D6 poor metabolisers , concomitant use of potent inhibitor of CYP3A4 may result in higher plasma concentration of aripiprazole compare to that in CYP2D6 extensive metabolizers .
& quot ;
& quot ; Bisphosphonate , ATC code :
& quot ;
& quot ; dose ( IU / kg give 3x / week )
& quot ;
& quot ; Tablet
& quot ;
& quot ; the total body clearance of aripiprazole be 0.7 ml / min / kg , which be primarily hepatic .
& quot ;
& quot ; Clinical manifestation of NMS be hyperpyrexia , muscle rigidity , alter
& quot ;
& quot ; the intravenous route have to be use ( please see section 4.4 - chronic renal failure patient ) .
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; Orodispersible Tablet
& quot ;
& quot ; only to be prepare and administer by personnel appropriately train in handle cytotoxics .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; 6 .
& quot ;
& quot ; 186 B .
& quot ;
& quot ; in clinical trial , rare case of NMS be report during treatment with aripiprazole .
& quot ;
& quot ; Abseamed 6000 IU / 0.6 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Hyperkalaemia have be observe in isolated case .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; 3 .
& quot ;
& quot ; 54 Pharmacokinetics in special patient group
& quot ;
& quot ; do not freeze .
& quot ;
& quot ; important information about some of the ingredient of ABILIFY if you have be tell by your doctor that you have an intolerance to some sugar , contact your doctor before take this medicine .
& quot ;
& quot ; 4 .
& quot ;
& quot ; - treatment of anaemia associate with chronic renal failure in paediatric and adult patient on
& quot ;
& quot ; ask your doctor or pharmacist for advice before take ABILIFY .
& quot ;
& quot ; Abseamed 2000 IU / 1 ml solution for injection in a pre-filled syringe
& quot ;
& quot ; Batch
& quot ;
& quot ; Neutropenia be dose-dependent and a dose-limiting toxicity .
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in
& quot ;
& quot ; Τηλ : + 30 210 6074300
& quot ;
& quot ; Uncommon side effect ( greater than 1 in 1,000 , le than 1 in 100 patient ) some people may have change in blood pressure , may feel dizzy , especially when get up from a lying or sit position , or may experience a fast heart rate , dry mouth or fatigue .
& quot ;
& quot ; - The other ingredient be sodium dihydrogen phosphate dihydrate , disodium phosphate
& quot ;
& quot ; when weak inhibitor of CYP3A4 ( e. g . , diltiazem or escitalopram ) or CYP2D6 be use concomitantly with ABILIFY , modest increase in aripiprazole concentration might be expect .
& quot ;
& quot ; 8 .
& quot ;
& quot ; rash , photosensitivity reaction , alopecia , hyperhidrosis
& quot ;
& quot ; expiry date
& quot ;
& quot ; in patient with chronic renal failure and clinically evident ischaemic heart disease or congestive heart failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration a recommend under section 4.2 .
& quot ;
& quot ; 99 1 .
& quot ;
& quot ; 12 .
& quot ;
& quot ; lot
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; 5 .
& quot ;
& quot ; 56-99 year ) of aripiprazole in elderly patient with psychosis associate with Alzheimer & apos ; s disease , patient treat with aripiprazole be at increase risk of death compare to placebo .
& quot ;
& quot ; you have severe disorder of blood circulation of the heart ( coronary heart disease ) , artery of the leg or arm ( peripheral arterial occlusive disease ) , neck vessel ( vascular disease of the carotids ) or the brain ( cerebrovascular disease ) you have a recent heart attack or stroke
& quot ;
& quot ; 6.4 Special precaution for storage
& quot ;
& quot ; it may be necessary to add or increase antihypertensive treatment .
& quot ;
& quot ; these report be base on in vitro finding from human tumour sample , but be of uncertain significance in the clinical situation .
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; - if the solution have be accidentally frozen .
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; 3 / 3
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ;
& quot ; further information
& quot ;
& quot ; 7 .
& quot ;
& quot ; name OF the MEDICINAL product
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; EU / 1 / 04 / 276 / 033
& quot ;
& quot ; name OF the MEDICINAL product AND route ( s ) OF administration
& quot ;
& quot ; in haemodialysed patient , a bolus injection may be give during the dialysis session through a suitable venous port in the dialysis line .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; 16 Annex III
& quot ;
& quot ; these trial include patient with or without psychotic feature and with or without a rapid-cycling course .
& quot ;
& quot ; due to intra-patient variability , occasional individual haemoglobin value for a patient above and below the desired haemoglobin level may be observe .
& quot ;
& quot ; the treatment be divide into two stage :
& quot ;
& quot ; in several controlled study , epoetins have not be show to improve overall survival or decrease the risk of tumour progression in patient with anaemia associate with cancer .
& quot ;
& quot ; special warning that the MEDICINAL product must be STORED out OF the reach AND sight OF child
& quot ;
& quot ; - decrease locoregional control in patient with advanced head and neck cancer receiving
& quot ;
& quot ; 174 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; if sign and symptom of tardive dyskinesia appear in a patient on ABILIFY , dose reduction or discontinuation should be consider .
& quot ;
& quot ; natural orange cream with other natural flavour
& quot ;
& quot ; there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa .
& quot ;
& quot ; Abseamed should be give by the intravenous route .
& quot ;
& quot ; this medicinal product must not be administer by intravenous infusion , or mixed with other medicinal product .
& quot ;
& quot ; at each step , the increase or reduction in dose should be of 25 IU / kg 3 time per week .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; when aripiprazole be administer concomitantly with either valproate or lithium , there be no clinically important change in valproate or lithium concentration .
& quot ;
& quot ; Abseamed
& quot ;
& quot ; other
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; table 1 list adverse reaction associate with the administration of Abraxane to patient from study in which Abraxane have be administer a a single agent at any dose in any indication ( N = 789 ) .
& quot ;
& quot ; inadequate thinning of the blood by heparin ( heparinisation ) may lead to occlusion of the dialysis system .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 15 mg administer on a once-a-day schedule without regard to meal a monotherapy or combination therapy ( see section 5.1 ) .
& quot ;
& quot ; - iron supplementation , e. g .
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; 25 package LEAFLET :
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; ABILIFY be indicate for the treatment of moderate to severe manic episode in Bipolar I Disorder and for the prevention of a new manic episode in patient who experience predominantly manic episode and whose manic episode respond to aripiprazole treatment ( see section 5.1 ) .
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; if you be concern that you be give more ABILIFY solution for injection than you feel necessary , tell your doctor or nurse of your concern .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Tel . : + 48 22 5796666
& quot ;
& quot ; Abseamed can be inject under the skin by the patient or their carer if they
& quot ;
& quot ; Tumour growth potential
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; ask your pharmacist how to dispose of medicine no longer require .
& quot ;
& quot ; start dose of 50 IU / kg 3 time per week by the intravenous route , follow if necessary by a dose increase with 25 IU / kg increment ( 3 time per week ) until the desired goal be achieve ( this should be do in step of at least four week ) .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; in two large , open-label study , 2697 cancer patient receive non-platinum chemotherapy be include , 1895 with solid tumour ( 683 breast , 260 lung , 174 gynaecological , 300 gastro-intestinal , and 478 other tumour type ) and 802 with haematological malignancy .
& quot ;
& quot ; 14 .
& quot ;
& quot ; in another 12-week trial , the incidence of EPS be 26.6 % for patient treat with aripiprazole and 17.6 % for those treat with lithium .
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; 10000 IU / 1.0 ml
& quot ;
& quot ; there be no experience of acute intoxication with Aclasta .
& quot ;
& quot ; Excipients
& quot ;
& quot ; if you have any further question on the use of this product , ask your doctor or pharmacist .
& quot ;
& quot ; however , in one of these trial , a fixed-dose trial , there be a significant dose response relationship for cerebrovascular adverse event in patient treat with aripiprazole .
& quot ;
& quot ; stability of reconstituted suspension in the vial :
& quot ;
& quot ; skin and subcutaneous tissue disorder :
& quot ;
& quot ; 5 .
& quot ;
& quot ; expiry date
& quot ;
& quot ; patient should be advise not to breast feed if they be take aripiprazole .
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; 84 year ; range :
& quot ;
& quot ; in clinical study , 10-30 mg / day dos of aripiprazole have no significant effect on the metabolism of substrate of CYP2D6 ( dextromethorphan / 3-methoxymorphinan ratio ) , 2C9 ( warfarin ) , 2C19 ( omeprazole ) , and 3A4 ( dextromethorphan ) .
& quot ;
& quot ; 48 The recommend dose be 600 IU / kg epoetin alfa , give weekly for three week ( day 21 , 14 and 7 ) prior to surgery and on the day of surgery ( day 0 ) .
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; 146 PARTICULARS to appear on the outer packaging
& quot ;
& quot ; EU / 1 / 05 / 308 / 001
& quot ;
& quot ; follow subcutaneous injection , serum level of epoetin alfa be much lower than the level achieve follow intravenous injection , the level increase slowly and reach a peak between 12 and
& quot ;
& quot ; EXP IRY date
& quot ;
& quot ; in three short-term ( 4 to 6 week ) placebo-controlled trial involve 1,228 schizophrenic patient , present with positive or negative symptom , aripiprazole be associate with statistically significantly greater improvement in psychotic symptom compare to placebo .
& quot ;
& quot ; weight gain : weight gain be commonly see in schizophrenic and bipolar mania patient due to co- morbidity , use of antipsychotic know to cause weight gain , poorly manage life-style , and might lead to severe complication .
& quot ;
& quot ; they may also have episode of depression .
& quot ;
& quot ; Aripiprazole should be use with caution in patient with known cardiovascular disease ( history of myocardial infarction or ischaemic heart disease , heart failure , or conduction abnormality ) , cerebrovascular disease , condition which would predispose patient to hypotension ( dehydration , hypovolemia , and treatment with antihypertensive medication ) or hypertension , include accelerate or malignant .
& quot ;
& quot ; Abraxis BioScience limit West Forest Gate Wellington Road Wokingham Berkshire RG40 2AQ United Kingdom
& quot ;
& quot ; Subcutaneous or intravenous use
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; EU / 1 / 04 / 276 / 003
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; 149 store in the original package in order to protect from moisture .
& quot ;
& quot ; 12 g / dl )
& quot ;
& quot ; 4.6 Pregnancy and lactation
& quot ;
& quot ; Activated charcoal ( 50 g ) , administer one hour after aripiprazole , decrease aripiprazole Cmax by about 41 % and AUC by about 51 % , suggest that charcoal may be effective in the treatment of overdose .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; 1 bottle - 100 ml component of a multi-pack comprising 5 bottle , each bottle of 100 ml .
& quot ;
& quot ; Tel : + 420 221 016 111
& quot ;
& quot ; it do not matter whether you take it with or without food .
& quot ;
& quot ; two other smaller , randomise , placebo-controlled trial fail to show a significant improvement in quality of life parameter on the EORTC-QLQ-C30 scale or CLAS , respectively .
& quot ;
& quot ; Epoetin alfa therapy should continue until one month after the end of chemotherapy .
& quot ;
& quot ; date OF first authorisation / renewal OF the authorisation
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; therefore , caution should be exercise when administer paclitaxel concomitantly with medicine know to inhibit ( e. g. erythromycin , fluoxetine , imidazole antifungal ) or induce ( e. g. rifampicin , carbamazepine , phenytoin , efavirenz , nevirapine ) either CYP2C8 or CYP3A4 .
& quot ;
& quot ; market authorisation holder
& quot ;
& quot ; 50 IU / kg 3 time per week by the intravenous route .
& quot ;
& quot ; specific drug-drug interaction study have not be conduct with zoledronic acid .
& quot ;
& quot ; Medice
& quot ;
& quot ; 101 further information on clinical trial :
& quot ;
& quot ; 10 mg
& quot ;
& quot ; however , the maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; EU number
& quot ;
& quot ; Correction for anaemia may lead to increase appetite , and potassium and protein intake .
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; Administer the amount require .
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; 1 / 1
& quot ;
& quot ; 1 .
& quot ;
& quot ; bottle ( PET )
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; in patient with chronic renal failure , maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommend in section 4.2 .
& quot ;
& quot ; lot
& quot ;
& quot ; result of an epidemiological study find that there be no increase risk of suicidality with aripiprazole compare to other antipsychotic among patient with bipolar disorder .
& quot ;
& quot ; study in animal have show reproduction toxicity ( see section 5.3 ) .
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; treatment of anaemia and reduction of transfusion requirement in adult patient receive chemotherapy for solid tumour , malignant lymphoma or multiple myeloma , and at risk of transfusion a assess by the patient & apos ; s general status ( e. g. cardiovascular status , pre-existing anaemia at the start of chemotherapy ) .
& quot ;
& quot ; take other medicine please tell your doctor or pharmacist if you be take or have recently take any other medicine , include medicine obtain without a prescription .
& quot ;
& quot ; - do not freeze .
& quot ;
& quot ; the recommend starting dose for ABILIFY be 10 or 15 mg / day with a maintenance dose of 15 mg / day administer on a once-a-day schedule without regard to meal .
& quot ;
& quot ; 1 vial
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; therefore , aripiprazole should be use with caution in patient who have a history of seizure disorder or have condition associate with seizure .
& quot ;
& quot ; for a full list of excipients , see section 6.1 .
& quot ;
& quot ; Batch
& quot ;
& quot ; ABILIFY be effective in maintain the clinical improvement during continuation therapy in patient who have show an initial treatment response .
& quot ;
& quot ; 12 .
& quot ;
& quot ; the powder be White to yellow .
& quot ;
& quot ; Aripiprazole exhibit antagonist property in animal model of dopaminergic hyperactivity and agonist property in animal model of dopaminergic hypoactivity .
& quot ;
& quot ; market authorisation number ( s )
& quot ;
& quot ; 5 .
& quot ;
& quot ; in order to ensure optimum response to epoetin alfa , adequate iron store should be assure :
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; may be harmful for people with phenylketonuria .
& quot ;
& quot ; try to take the ABILIFY tablet at the same time each day .
& quot ;
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; Meta-analysis of overall survival data produce a hazard ratio point estimate of 1.08 in favour of control ( 95 % CI :
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; take ABILIFY with some medicine may need to change your dose of ABILIFY .
& quot ;
& quot ; in addition , special precaution should be take in patient with predisposition for development of deep vein thrombosis ( DVTs ) .
& quot ;
& quot ; when concomitant administration of potent CYP3A4 inducer with aripiprazole occurs , the aripiprazole dose should be increase .
& quot ;
& quot ; 129 Correction phase :
& quot ;
& quot ; invent name
& quot ;
& quot ; also contain : lactose monohydrate .
& quot ;
& quot ; what ABILIFY look like and content of the Pack ABILIFY 30 mg orodispersible tablet be round and pink , mark with & quot ; & quot ; A & quot ; & quot ; over & quot ; & quot ; 643 & quot ; & quot ; on one side and 30 on the other .
& quot ;
& quot ; dose adjustment in order to maintain haemoglobin value at the desired level :
& quot ;
& quot ; 1 .
& quot ;
& quot ; agitation , nervousness ; suicide attempt , suicidal ideation , and complete suicide ( see section 4.4 )
& quot ;
& quot ; if a patient develop sign and symptom indicative of NMS , or present with unexplained high fever without additional clinical manifestation of NMS , all antipsychotic medicinal product , include ABILIFY , must be discontinue .
& quot ;
& quot ; pre-filled syringe ( glass )
& quot ;
& quot ; Medice Arzneimittel Pütter GmbH & amp ; Co kg , Kuhloweg 37 , D-58638 Iserlohn , Germany
& quot ;
& quot ; ABILIFY dose should be reduce to approximately one-half of it prescribed dose when concomitant administration of ABILIFY with quinidine occurs .
& quot ;
& quot ; ABILIFY
& quot ;
& quot ; study in animal have show reproductive toxicity ( see section 5.3 ) .
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; although there be no information on the effect of haemodialysis in treat an overdose with aripiprazole , haemodialysis be unlikely to be useful in overdose management since aripiprazole be highly bind to plasma protein .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; patient should be monitor closely to ensure that the lowest approve dose of Epoetin alfa be use to provide adequate control of the symptom of anaemia .
& quot ;
& quot ; 1 .
& quot ;
& quot ; 5 .
& quot ;
& quot ; other special warning ( s ) , if necessary
& quot ;
& quot ; due to insufficient safety information in human and concern raise by animal reproductive study , this medicinal product should not be use in pregnancy unless the expected benefit clearly justify the potential risk to the foetus .
& quot ;
& quot ; Hypersensitivity to the active substance or to any of the excipients .
& quot ;
& quot ; EU / 1 / 07 / 412 / 013 EU / 1 / 07 / 412 / 014
& quot ;
& quot ; other
& quot ;
& quot ; Aripiprazole be widely distribute throughout the body with an apparent volume of distribution of 4.9 l / kg , indicate extensive extravascular distribution .
& quot ;
& quot ; the protein fraction of the molecule contribute about 58 % and consist of 165 amino acid .
& quot ;
& quot ; these change be interpret a be secondary to decreased maternal body weight gain .
& quot ;
& quot ; Č eská republika BRISTOL-MYERS SQUIBB SPOL .
& quot ;
& quot ; BATCH number
& quot ;
& quot ; read all of this leaflet carefully before you be give this medicine .
& quot ;
& quot ; Haemoglobin variability should be address through dose management , with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; 200 mg oral elemental iron daily ) throughout the course of treatment .
& quot ;
& quot ; however , since cyclosporin be bind by red blood cell there be potential for an interaction .
& quot ;
& quot ; Non-clinical safety data reveal no special hazard for human base on conventional study of safety pharmacology , repeat-dose toxicity , genotoxicity , carcinogenic potential , and toxicity to reproduction .
& quot ;
& quot ; 48 Dysphagia : oesophageal dysmotility and aspiration have be associate with antipsychotic drug use , include ABILIFY .
& quot ;
& quot ; these measure will help to protect the environment .
& quot ;
& quot ; your doctor will weight this risk carefully against the benefit to be derive from treatment with epoetin alfa .
& quot ;
& quot ; it may harm them , even if their symptom be the same a yours .
& quot ;
& quot ; Correction phase :
& quot ;
& quot ; instruction on use
& quot ;
& quot ; gender :
& quot ;
& quot ; keep out of the reach and sight of child .
& quot ;
& quot ; 100 mg
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; a calibrated measuring cup and a 2 ml calibrate dropper be include in the carton .
& quot ;
& quot ; you may need to read it again .
& quot ;
& quot ; very common ( ≥ 1 / 10 ) , common ( ≥ 1 / 100 , & lt ; 1 / 10 ) , uncommon ( ≥ 1 / 1,000 , & lt ; 1 / 100 ) , rare ( ≥ 1 / 10,000 , & lt ; 1 / 1,000 ) adverse drug reaction be show in table 1 .
& quot ;
& quot ; temperature regulation disorder ( e. g. hypothermia , pyrexia ) , chest pain , peripheral oedema
& quot ;
& quot ; 106 A manufacturing authorisation holder responsible for BATCH release
& quot ;
& quot ; 11 Reconstitution and administration of the product :
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; in particular , no residue of the cell line use for the production be detectable at the concentration of the active ingredient that be use in human .
& quot ;
& quot ; patient should have their serum creatinine level measure before receive Aclasta .
& quot ;
& quot ; 7.7
& quot ;
& quot ; 1 bottle
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; 2 maximum daily dose of 30 mg should be use with caution in patient with severe hepatic impairment ( see section 5.2 ) .
& quot ;
& quot ; Abseamed can be use to increase the yield of autologous blood from patient in a predonation programme .
& quot ;
& quot ; detail information on this medicine be available on the European Medicines Agency ( EMEA ) web site : http : / / www . emea . europa . EU /
& quot ;
& quot ; Epoetin alfa do not show any change in bacterial and mammalian cell culture mutagenicity test and an in vivo micronucleus test in mouse .
& quot ;
& quot ; Metabolism and nutrition disorder :
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ; ABILIFY 7.5 mg / ml solution for Injection aripiprazole
& quot ;
& quot ; Abilify
& quot ;
& quot ; method AND route ( s ) OF administration
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; in addition , other cause of anaemia , such a vitamin B12 or folate deficiency , should be exclude before institute therapy with epoetin alfa .
& quot ;
& quot ; however , you should not dilute with other liquid or mix with other food prior to take ABILIFY oral solution .
& quot ;
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; other infrequently report side effect :
& quot ;
& quot ; • condition or restriction with regard to the safe AND effective use OF the MEDICINAL product
& quot ;
& quot ; Haemoglobin variability should be address through dose management with consideration for the haemoglobin target range of 10 g / dl ( 6.2 mmol / l ) to 12 g / dl ( 7.5 mmol / l ) .
& quot ;
& quot ; 4.2 Posology and method of administration
& quot ;
& quot ; when the CYP3A4 or CYP2D6 inhibitor be withdraw from the combination therapy , aripiprazole dose should then be increase ( see section 4.5 ) .
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; the recommended dosing regimen be describe in the following diagram :
& quot ;
& quot ; 3 .
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; - if you have develop pure red Cell Aplasia ( reduce or stop production of red blood cell )
& quot ;
& quot ; all patient receive adequate supplementation with vitamin D and calcium in the post-menopausal osteoporosis trial , the prevention of clinical fracture after hip fracture trial , and the Paget ’ s disease trial ( see also section 4.2 ) .
& quot ;
& quot ; maintenance phase :
& quot ;
& quot ; consequently , haemoglobin and blood pressure should be closely monitor .
& quot ;
& quot ; B-CTx be significantly reduce by 61 % below baseline level at 12 month and be sustain at 55 % below baseline level at 36 month .
& quot ;
& quot ; this leaflet be last approved in
& quot ;
& quot ; expiry date
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; Erythropoietin receptor may be express on the surface of a variety of tumour cell .
& quot ;
& quot ; Haemoglobin level should be measure on a regular basis until a stable level be achieve and periodically thereafter .
& quot ;
& quot ; the reconstitute suspension have a pH of 6-7.5 and an osmolality of 300-360 mOsm / kg .
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; Aclasta contain the same active substance find in Zometa ( zoledronic acid ) , use for oncology indication , and a patient be treat with Zometa should not be treat with Aclasta .
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; in another long-term 26-week control trial , the incidence of EPS be 14.8 % for aripiprazole-treated patient and 15.1 % for olanzapine-treated patient .
& quot ;
& quot ; Reproductive system and breast disorder :
& quot ;
& quot ; patient should not be retreat with subsequent cycle of Abraxane until neutrophil recover to & gt ; 1.5 X 109 / l and platelet recover to & gt ; 100 X 109 / l .
& quot ;
& quot ; Medicinal product subject to medical prescription .
& quot ;
& quot ; for 4 week
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; alternatively , epoetin alfa can be administer at an initial dose of 450 IU / kg subcutaneously once weekly .
& quot ;
& quot ; ABILIFY 10 mg orodispersible tablet aripiprazole
& quot ;
& quot ; early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid , for example , be recommend in these patient .
& quot ;
& quot ; France BRISTOL-MYERS SQUIBB SARL Tél : + 33 ( 0 ) 810 410 500
& quot ;
& quot ; 5 .
& quot ;
& quot ; Medice
& quot ;
& quot ; 7 .
& quot ;
& quot ; Tél / Tel : + 32 2 352 74 60
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd commit to provide a PSUR at 6 monthly interval unless otherwise decide by the CHMP .
& quot ;
& quot ; Intramuscular use
& quot ;
& quot ; 3000 IU / 0.3 ml
& quot ;
& quot ; Tel : + 39 06 50 39 61
& quot ;
& quot ; care should be take to ensure that at the outset of the treatment patient be not iron deficient .
& quot ;
& quot ; Pack of 1 or 6 syrinx .
& quot ;
& quot ; what ABILIFY contain The active substance be aripiprazole .
& quot ;
& quot ; treatment of adult patient schedule for major elective orthopaedic surgery :
& quot ;
& quot ; information for the user
& quot ;
& quot ; Reticulocyte count increase ≥ 40,000 / µl or Hb increase ≥ 1 g / dl
& quot ;
& quot ; if haemoglobin have increase by at least 1 g / dl ( 0.62 mmol / l ) or the reticulocyte count have increase ≥ 40,000 cell / µl above baseline after 4 week of treatment , the dose should remain at 150 IU / kg 3 time a week or 450 IU / kg once weekly .
& quot ;
& quot ; you will also take iron supplement before and during Abseamed treatment to increase the effectiveness of Abseamed .
& quot ;
& quot ; Pre-filled syrinx ( glass type I ) with plunger ( Teflon-faced rubber ) seal in a blister .
& quot ;
& quot ; in two 3-week , flexible-dose , placebo-controlled monotherapy trial involve patient with a manic or mixed episode of Bipolar I Disorder , aripiprazole demonstrate superior efficacy to placebo in
& quot ;
& quot ; general
& quot ;
& quot ; 4 .
& quot ;
& quot ; this be especially important for the elderly and for patient receive diuretic therapy .
& quot ;
& quot ; 3 .
& quot ;
& quot ; it be use to treat adult who suffer from a disease characterise by symptom such a hearing , see or sense thing which be not there , suspiciousness , mistaken belief , incoherent speech and behaviour and emotional flatness .
& quot ;
& quot ; LABELLING
& quot ;
& quot ; maintenance dose between 25 and 50 IU / kg 2 time per week into 2 equal injection .
& quot ;
& quot ; 3 year
& quot ;
& quot ; Erythropoietins be growth factor that primarily stimulate red blood cell production .
& quot ;
& quot ; 14 for the purpose of ambulatory use , the patient may remove Abseamed from the refrigerator and store it not above 25 ° C for one single period of up to 3 day .
& quot ;
& quot ; attention should be pay to sudden stab migraine-like headache a a possible warning signal .
& quot ;
& quot ; read the package leaflet before use .
& quot ;
& quot ; Pharmacotherapeutic group : antianaemic , ATC code :
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; therefore , the company withdraw it application for the use of Abraxane a first-line treatment during the assessment of the medicine .
& quot ;
& quot ; Endocrine disorder :
& quot ;
& quot ; no other erythropoietic therapy should be commence because of the risk of cross-reaction .
& quot ;
& quot ; 13 Annex II
& quot ;
& quot ; PHARMACOLOGICAL PROPERTIES
& quot ;
& quot ; Hypertensive crisis with encephalopathy-like symptom can occur .
& quot ;
& quot ; 4 June 2004
& quot ;
& quot ; non response to epoetin alfa therapy may have the following cause : iron , folate , or vitamin B12 deficiency ; aluminium intoxication ; intercurrent infection ; inflammatory or traumatic episode ; occult blood loss ; haemolysis , and bone marrow fibrosis of any origin .
& quot ;
& quot ; Subcutaneous injection : a maximum volume of 1 ml at one injection site should generally not be exceed .
& quot ;
& quot ; the frequency list below be define use the following convention : common ( & gt ; 1 / 100 , & lt ; 1 / 10 ) and uncommon ( & gt ; 1 / 1 , 000 , & lt ; 1 / 100 ) .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Solvent-based paclitaxel ( 175 mg / m2 )
& quot ;
& quot ; the symptom be usually transient , typically occur three day after Abraxane administration and resolve within a week .
& quot ;
& quot ; Subcutaneous route
& quot ;
& quot ; Maternal toxicity occur at dos similar to those elicit developmental toxicity .
& quot ;
& quot ; adult surgery patient in an autologous predonation programme :
& quot ;
& quot ; Smoking and race :
& quot ;
& quot ; potential for other medicinal product to affect ABILIFY :
& quot ;
& quot ; solution for injection in a pre-filled syringe .
& quot ;
& quot ; good blood management practice should always be use in the perisurgical setting
& quot ;
& quot ; a single-dose study in subject with vary degree of liver cirrhosis ( Child-Pugh class A , B , and C ) do not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole , but the study include only 3 patient with class C liver cirrhosis , which be insufficient to draw conclusion on their metabolic capacity .
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; other
& quot ;
& quot ; if you be give other medicine a part of your treatment , you should ask your doctor for advice on driving and use machine .
& quot ;
& quot ; all special warning and precaution associate with autologous predonation programme , especially routine volume replacement , should be respect .
& quot ;
& quot ; follow concomitant administration of carbamazepine , a potent inducer of CYP3A4 , the geometric mean of Cmax and AUC for aripiprazole be 68 % and 73 % lower , respectively , compare to when aripiprazole ( 30 mg ) be administer alone .
& quot ;
& quot ; 13 .
& quot ;
& quot ; undesirable effect know to be associate with antipsychotic therapy and also report during treatment with aripiprazole include neuroleptic malignant syndrome , tardive dyskinesia , seizure , cerebrovascular adverse event and increased mortality in elderly demented patient , hyperglycaemia and diabetes mellitus ( see section 4.4 ) .
& quot ;
& quot ; Ελλάδα ΜΕΝΤΙΣΙ ΕΛΛΑΣ Τηλ : + 30 ( 0 ) 210 9960971
& quot ;
& quot ; expiry date
& quot ;
& quot ; 49 X 1
& quot ;
& quot ; if anti-erythropoietin , antibody-mediated PRCA be suspect , therapy with Abseamed should be discontinue immediately .
& quot ;
& quot ; in the open-label study there be no difference in overall survival between patient treat with recombinant human erythropoietin and control .
& quot ;
& quot ; Abilify
& quot ;
& quot ; interaction with receptor other than dopamine and serotonin subtypes may explain some of the other clinical effect of aripiprazole .
& quot ;
& quot ; Otsuka pharmaceutical Europe Ltd .
& quot ;
& quot ; Abilify
& quot ;
& quot ; the use of epoetin alfa in patient schedule for major elective orthopaedic surgery and not participate in an autologous blood predonation programme be contraindicate in patient with severe coronary , peripheral arterial , carotid or cerebral vascular disease , include patient with recent myocardial infarction or cerebral vascular accident .
& quot ;
& quot ; ask your doctor or pharmacist for advice before take any medicine .
& quot ;
& quot ; Gastrointestinal disorder :
& quot ;
& quot ; oral use
& quot ;
& quot ; manufacturer
& quot ;
& quot ; pure red Cell Aplasia ( PRCA ) Antibody-mediated PRCA have be very rarely report after month to year of subcutaneous erythropoietin treatment .
& quot ;
& quot ; 1 pre-filled syringe of 0.5 ml contains 1000 international unit ( IU ) correspond to 8.4 microgram epoetin alfa
& quot ;
& quot ; close supervision of high-risk patient should accompany antipsychotic therapy .
& quot ;
& quot ; 191 Cancer patient or patient schedule for major orthopaedic surgery
& quot ;
& quot ; this medicine have be prescribe for you .
& quot ;
& quot ; 4 .
& quot ;
& quot ; 300 IU / kg 3x / week for 4 week
& quot ;
& quot ; haemodialysis and adult patient on peritoneal dialysis ( see section 4.4 ) .
& quot ;
& quot ; a sustained haemoglobin level of greater than 12 g / dl ( 7.5 mmol / l ) should be avoid .
& quot ;
& quot ; 13 .
& quot ;
& quot ; 3 / 3
& quot ;
& quot ; John & apos ; s Wort ) may be expect to have similar effect and similar dose increase should therefore be apply .
& quot ;
& quot ; 4 .
& quot ;
& quot ; Tel . : + 36 1 301 9700
& quot ;
& quot ; label / SYRINGE
& quot ;
& quot ; for subcutaneous and intravenous use .
& quot ;
& quot ; 6 .
& quot ;
& quot ; this regress during the course of continued therapy .
& quot ;
& quot ; EU / 1 / 07 / 412 / 001 EU / 1 / 07 / 412 / 002
& quot ;
& quot ; Aripiprazole dose range from 0.5 to 30 mg administer once a day to healthy subject for 2 week produce a dose-dependent reduction in the binding of 11C-raclopride , a D2 / D3 receptor ligand , to the caudate and putamen detect by positron emission tomography .
& quot ;
& quot ; list OF EXCIPIENTS
& quot ;
& quot ; information in BRAILLE
& quot ;
& quot ; România BRISTOL-MYERS SQUIBB GYÓGYSZERKERESKEDELMI KFT .
& quot ;
& quot ; instruction on use
& quot ;
& quot ; if you need more information about your medical condition or your treatment , read the package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
& quot ;
& quot ; further information
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; Dosage adjustment to maintain haemoglobin concentration between 10 g / dl - 12 g / dl :
& quot ;
& quot ; it explain how the Committee for Medicinal product for Human use ( CHMP ) assess the study perform , to reach their recommendation on how to use the medicine .
& quot ;
& quot ; Cardiac disorder :
& quot ;
& quot ; store in the original package in order to protect from moisture .
& quot ;
& quot ; thus patient receive Abraxane should be vigilantly monitor by physician for the occurrence of cardiac event .
& quot ;
& quot ; oral use
& quot ;
& quot ; elderly patient :
& quot ;
& quot ; in animal study , epoetin alfa have be show to decrease foetal body weight , delay ossification and increase foetal mortality when give in weekly dos of approximately 20 time the recommended human weekly dose .
& quot ;
& quot ; Τηλ : + 357 22 677038
& quot ;
& quot ; Medicines should not be dispose of via wastewater or household waste .
& quot ;
& quot ; during antipsychotic treatment , improvement in the patient & apos ; s clinical condition may take several day to some week .
& quot ;
& quot ; the Abseamed pre-filled syringe be ready for use .
& quot ;
& quot ; the maximum dose should not exceed 200 IU / kg 3 time per week .
& quot ;
& quot ; when perform haematologic assessment during the preoperative period , if the haemoglobin level reach 15 g / dl , or higher , administration of epoetin alfa should be stop and further dos should not be give .
& quot ;
& quot ; the orodispersible tablet can be take with or without liquid .
& quot ;
& quot ; use a sterile syringe , 20 ml of sodium chloride 9 mg / ml ( 0.9 % ) solution for infusion should be inject into a vial of Abraxane over a minimum of 1 minute .
& quot ;
& quot ; when concomitant administration of ketoconozole with ABILIFY occurs , ABILIFY dose should be reduce to approximately one-half of it prescribed dose .
& quot ;
& quot ; Abraxane
& quot ;
& quot ; European Medicines Agency
& quot ;
& quot ; Absorption :
& quot ;
& quot ; statement OF active substance ( s )
& quot ;
& quot ; 6.3 Shelf life
& quot ;
& quot ; Nederland BRISTOL-MYERS SQUIBB BV Tel : + 31 34 857 42 22
& quot ;
& quot ; Intravenous injection : over at least one to five minute , depend on the total dose .
& quot ;
& quot ; 6.6 Special precaution for disposal and other handling
& quot ;
& quot ; no evidence exist that indicate an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimen in vitro .
& quot ;
& quot ; rhabdomyolysis , myalgia , stiffness
& quot ;
& quot ; not applicable .
& quot ;
& quot ; in the four placebo-controlled study the hazard ratio for overall survival range between 1.25 and 2.47 in favour of control .
& quot ;
& quot ; Erythropoietin be a glycoprotein that stimulate , a a mitosis-stimulating factor and differentiate hormone , the formation of erythrocyte from precursor of the stem cell compartment .
& quot ;
& quot ; Aseptic technique must be follow during the preparation of the infusion .
& quot ;
& quot ; 78 Pharmacokinetics in special patient group
& quot ;
& quot ; pharmaceutical PARTICULARS
& quot ;
& quot ; the recommended total weekly dose be between 75 and 300 IU / kg give by the intravenous route .
& quot ;
& quot ; 4.3 Contraindications
& quot ;
& quot ; urinary incontinence , urinary retention
& quot ;
& quot ; 5.1 Pharmacodynamic property
& quot ;
& quot ; in cancer patient receive chemotherapy , the 2 - 3 week delay between epoetin alfa administration and the appearance of erythropoietin-induced red cell should be take into account when assess if epoetin alfa therapy be appropriate ( patient at risk of be transfuse ) .
& quot ;
& quot ; Abraxane 5 mg / ml powder for suspension for infusion Paclitaxel
& quot ;
& quot ; 5 .
& quot ;
& quot ;
& quot ; this difference be not statistically significant .
& quot ;
& quot ; 82.4 year ; range :
& quot ;
& quot ; 148 minimum PARTICULARS to appear on BLISTERS or STRIPS
& quot ;
& quot ; the study either recruited patient who be be treat with chemotherapy ( two study ) or use patient population in which erythropoiesis stimulating agent be not indicate : anaemia in patient with cancer not receive chemotherapy , and head and neck cancer patient receive radiotherapy .
& quot ;
& quot ; oral solution
& quot ;
& quot ; Epoetin alfa
& quot ;
& quot ; Renal disease :
& quot ;
& quot ; solution for injection in a pre-filled syringe
& quot ;
& quot ; another study compare Abilify with haloperidol over 12 week in 347 patient , and a further study compare the effectiveness of Abilify and placebo in prevent recurrence in 160 patient whose manic symptom have already be stabilise use Abilify .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; possible side effect
& quot ;
& quot ; in controlled clinical study , use of Epoetin alfa and other erythropoiesis-stimulating agent ( ESAs ) have show :
& quot ;
& quot ; alternatively , disperse the tablet in water and drink the resulting suspension .
& quot ;
& quot ; if the haemoglobin increase be & lt ; 1 g / dl ( & lt ; 0.62 mmol / l ) and the reticulocyte count have increase & lt ; 40,000 cell / µl above baseline , increase the dose to 300 IU / kg 3 time per week .
& quot ;
& quot ; bottle ( PET )
& quot ;
& quot ; which measure be be take to ensure the safe use of Abseamed ?
& quot ;
& quot ; 7 .
& quot ;
& quot ; in clinical trial and post-marketing experience , accidental or intentional acute overdosage of aripiprazole alone be identify in adult patient with report estimate dose up to 1,260 mg with no fatality .
& quot ;
& quot ; Vascular disorder :
& quot ;
& quot ; Comparisons between aripiprazole and placebo in the proportion of patient experience potentially clinically significant change in routine laboratory parameter reveal no medically important difference .
& quot ;
& quot ; the overall completion rate be significantly higher for patient on aripiprazole ( 43 % ) than for haloperidol ( 30 % ) .
& quot ;
& quot ; 6.5 Nature and content of container
& quot ;
& quot ; Abseamed be a sterile but unpreserved product and be for single use only .
& quot ;
& quot ; the pharmacokinetic characteristic of aripiprazole and dehydro-aripiprazole be find to be similar in patient with severe renal disease compare to young healthy subject .
& quot ;
